Originally published In Press as doi:10.1074/jbc.M108366200 on December 26, 2001
J. Biol. Chem., Vol. 277, Issue 12, 10573-10580, March 22, 2002
MEK Kinase 1 Induces Mitochondrial Permeability Transition
Leading to Apoptosis Independent of Cytochrome c
Release*
Erika M.
Gibson
,
Elizabeth S.
Henson
,
Jacylyn
Villanueva
, and
Spencer B.
Gibson
§
From the
Manitoba Institute of Cell Biology,
Winnipeg, Manitoba R3E 0V9, Canada
Received for publication, August 30, 2001, and in revised form, December 14, 2001
 |
ABSTRACT |
Induction of apoptosis often converges on the
mitochondria to induce permeability transition and release of apoptotic
proteins into the cytoplasm resulting in the biochemical and
morphological alteration of apoptosis. Activation of a serine threonine
kinase MEK kinase 1 (MEKK1) is involved in the induction of apoptosis. Expression of a kinase-inactive MEKK1 blocks genotoxin-induced apoptosis. Upon apoptotic stimulation, MEKK1 is cleaved into a 91-kDa
kinase fragment that further induces an apoptotic response. Mutation of
a consensus caspase 3 site in MEKK1 prevents its induction of
apoptosis. The mechanism of MEKK1-induced apoptosis downstream of
its cleavage, however, is unknown. Herein we demonstrate that full-length and cleaved MEKK1 leads to permeability transition in the
mitochondria. This permeability transition occurs through opening of
the permeability transition (PT) pore. Inhibiting PT pore opening and
reactive oxygen species production effectively reduced MEKK1-induced
apoptosis. Overexpression of MEKK1, however, failed to release
cytochrome c from the mitochondria or activate caspase 9. Since Bcl2 regulates changes in mitochondria and blocks MEKK1-induced
apoptosis, we determined that Bcl2 blocks MEKK1-induced apoptosis when
targeted to the mitochondria. This occurs downstream of MEKK1 cleavage,
since Bcl2 fails to block cleavage of MEKK1. In mouse embryonic
fibroblast cells lacking caspase 3, the cleaved but not full-length
MEKK1 induces apoptosis and permeability transition in the
mitochondria. Overall, this suggests that cleaved MEKK1 leads to
permeability transition contributing to MEKK1-induced apoptosis
independent of cytochrome c release from the mitochondria.
 |
INTRODUCTION |
Apoptotic signals often lead to changes in the mitochondria. These
changes consist of mitochondrial permeability transition, production of
reactive oxygen species
(ROS),1 and release of
proteins into the cytoplasm (1, 2). These events could cause blockage
of ATP production, damage to membranes, DNA condensation, and
activation of caspases leading to apoptosis (1-4). In response to
apoptotic stimulation, the mitochondrial membrane opens to allow
solutes and water to enter the mitochondria. This is controlled by a
multiprotein complex found in the inner and outer membranes of the
mitochondria known as the permeability transition (PT) pore (2, 5, 6).
The PT pore consists of voltage-dependent anion
channel/porin, adenine nucleotide translocator, cyclophilin D, creatine
kinases, and other proteins (6, 7). Upon PT pore opening, the
mitochondria loses its membrane potential (
m) across
the inner membrane. This often occurs following apoptotic stimuli. This
is associated with increased production of ROS that further damages
proteins and membranes (6, 7). In addition, proteins are released from
the mitochondria following apoptotic stimulus such as cytochrome
c. When cytochrome c is released, it binds to an
Apaf1 and caspase 9 complex (1, 4, 8). This leads to caspase 9 activation, causing cleavage of specific proteins and activation of
other caspases. These mitochondrial events regulate the induction of apoptosis.
The Bcl2 family of proteins control mitochrondial apoptotic responses
(9). Bcl2 family members consist of pro- and antiapoptotic proteins
(10, 11). Proapoptotic Bcl2 family members translocate to the outer
membrane of the mitochondria from the cytosol following an apoptotic
signal (11). This translocation results in release of cytochrome
c into the cytosol and opening of the PT pore. The exact
mechanism of how these proteins release mitochondrial cytochrome c or open the PT pore remains unclear. Anti-apoptotic Bcl2
family members such as Bcl2 itself can reverse the effects of the
pro-apoptotic members (9). Bcl2 expression effectively blocks the PT
pore opening and cytochrome c release. This is accomplished
through Bcl2 binding to pro-apoptotic Bcl2 family members, forming
heterodimers. This inhibits these pro-apoptotic proteins from opening
the PT pore and releasing cytochrome c from the mitochondria
(9, 11). This interplay between pro- and anti-apoptotic Bcl2 family
members regulates the role of the mitochondria in apoptosis.
MEK kinase 1 (MEKK1) is a serine threonine kinase that when
overexpressed induces caspase activation and apoptosis (12, 13). Many
apoptotic stimuli including genotoxic agents activate MEKK1 kinase
activity (12, 14). Following genotoxin treatment, MEKK1 activation
leads to increased expression of death receptors such as Fas and
death receptors 4 and 5, presumably through activation of transcription
factors such as NF-
B (15). This up-regulation of death receptors
contributes to genotoxin-induced apoptosis. Following treatment with
apoptotic stimuli, MEKK1 is cleaved by caspases into a 91-kDa
fragment containing the kinase domain (13, 16). Overexpression of this
cleaved product is more potent at activating caspases and inducing
apoptosis than full-length MEKK1 (13). Cleavage of MEKK1 is dependent
on caspase 3-like molecules, since MEKK1 contains a consensus site for
caspase 3 cleavage, and caspase 3 inhibitors block MEKK1
cleavage. Mutation of this cleavage site prevents MEKK1-induced
apoptosis following expression in cells (13). MEKK1-induced apoptosis
is dependent on its kinase activity, since expression of a
kinase-inactive form of MEKK1 fails to induce apoptosis (14, 16).
Indeed, kinase inactive MEKK1 acts as a dominant negative
protein blocking apoptosis following genotoxin treatment (14, 16).
The downstream mechanism of MEKK1 induction of apoptosis following
caspase cleavage, however, remains unknown.
Herein, we demonstrate that overexpression of MEKK1 suppresses
mitochondrial 
m mediated by opening of the PT pore.
Inhibiting the PT pore and ROS formation effectively reduced
MEKK1-induced apoptosis. Furthermore, full-length MEKK1 expression
fails to suppress 
m or induce apoptosis in mouse
embryonic fibroblasts (MEFs) lacking caspase 3, whereas the 91-kDa
kinase fragment still is capable of 
m suppression and
induction of apoptosis in these cells. However, MEKK1 fails to release
cytochrome c from the mitochondria. This provides evidence
that MEKK1 cleavage causes permeability transition, leading to
apoptosis independent of cytochrome c release.
 |
MATERIALS AND METHODS |
Cell Culture--
Human embryonic kidney (HEK) 293 cells, breast
cancer cell line MCF-7, and human transformed cell line HeLa were
maintained in a humidified 5.0% CO2, 37 °C incubator in
Dulbecco's modified medium supplemented with 100 units/ml penicillin,
100 µg/ml streptomycin (Invitrogen). Medium for HEK 293 and
MCF-7 cells was supplemented with 10% fetal bovine serum (Invitrogen).
Primary MEF cells were maintained in minimum essential medium
supplemented with 10% fetal bovine serum (kind gift from Dr. Tak Mak,
Amigen Institute). HEK 293 cells expressing vector alone, MEKK1 KM and
Bcl2 proteins were under selection with 1 mg/ml G418 (Invitrogen).
MCF-7 cells expressing vector alone, Bcl2 wild type, and Bcl2 targeted
to the mitochondria (Bcl2-mito) were under selection with 0.5 mg/ml G418 as previously described (17) (kind gift from Dr. David Andrews,
McMaster University). HeLa cells overexpressing superoxide dismutase
were maintained in 0.2 mg/ml G418 (kind gift from Dr. Charles Epstein,
University of California, San Francisco).
Transfections--
HEK 293 cells were grown on glass coverslips.
They were co-transfected with 2 µg of pGFP containing cDNA for
green fluorescent protein (GFP; CLONTECH),
pcDNA containing the cDNA for MEKK1, kinase-inactive MEKK1, or
the 91-kDa form of MEKK1 using the LipofectAMINE technique (Invitrogen)
as per the manufacturer's instructions. The transfection efficiency
was about 20%. MCF-7, HeLa, and MEF cells were also grown on
coverslips and transfected with 8 µg of plasmid DNA as described
above using a Geneporter (GTS systems) as per the manufacturer's
instructions. The transfection efficiency was 30% for MCF-7 cells,
20% for HeLa cells, and 10% for MEF cells. Cells were viable
following transfection, and background apoptosis was 10%.

m Determination by Flow Cytometry
and Fluorometry--
HEK 293 and MEF cells were grown in 100-mm tissue
culture plates (flow cytometry) or on large coverslips (fluorometry).
HEK 293 cells grown on plates were transfected with cDNA for GFP
alone, MEKK1, kinase-inactive MEKK1 (MEKK1 KM), or 91-kDa MEKK1 as
described above. After 24 h of incubation, the cells were
resuspended in 1× Hepes-buffered saline solution (HBSS) and spun down
at 1200 rpm for 2 min. One ml of 1× HBSS was used to resuspend the
cells, and the cells were counted. Cells (1 × 106)
were diluted in 1× HBSS, and 500-µl aliquots were placed into 1.5-ml
centrifuge tubes. Tetramethylrhodamine (TMRM; Molecular Probes, Inc.,
Eugene, OR) was added to the appropriate tube at 150 µM
final concentration and incubated in the dark at room temperature for
15 min. The cells were then spun down and analyzed by a Becton Dickinson Facscaliber E2807 flow cytometer. FL-1 detects green fluorescence at 530-585 nm, whereas FL-2 detects red
fluorescence at 488-635 nm. The compensation for FL1 was 18% of FL2,
and compensation for FL2 was 58% of FL1. FL1 was gated for green
fluorescent protein-positive events, and these positive events were
further gated for FL2 (TMRM)-positive events. These gates remained
unchanged for each condition tested. The number of FL1-positive
compared with FL2-negative events was calculated as the percentage of

m suppression. Cells under each condition tested were
analyzed for 20,000 events on the flow cytometer. HEK 293 cells stably
expressing vector alone or MEKK1 KM were treated with 100 µM etoposide and stained for TMRM as described above. For
HEK 293 cells grown on coverslips, the cells were transfected with
cDNA for GFP (2 µg) or GFP fused to MEKK1 (2 µg). For MEF cells, the cells were transfected with GFP alone (0.8 µg) or in combination with MEKK1 (8 µg) or 91-kDa MEKK1 (8 µg) using
Geneporter as per the manufacturer's instructions. After transfection,
these cells were washed four times in 1× HBSS, and vacuum grease was applied to the edges of the coverslip. The cells were then stained with
150 µM TMRM in 1× HBSS. The coverslip was washed four
times with 1× HBSS and analyzed on an Olympus IX70 inverted confocal laser microscope using Flouview 2.0 software.
PT Pore Opening--
HEK 293 cells were grown on coverslips and
transfected with cDNA for red fluorescent protein (RFP; 0.2 µg)
or in combination with MEKK1 (2 µg) or 91-kDa MEKK1 (2 µg) using
LiptofectAMINE as per the manufacturer's instructions. The cells were
washed in 1× HBSS and stained with 5 mM CalceinAM
(Molecular Probes) and 5 mM CoCl2 (Sigma) for
15 min (18). The coverslips were then washed four times with 1× HBSS
and analyzed on an Olympus IX70 inverted confocal laser microscope
using Flouview 2.0 software.
Immunohistochemistry and Apoptosis Measurement--
Transfected
HEK 293 cells were untreated or treated with 20 µM
cyclosporin A (CsA) or 5 mM 4,5-dihydroxy-1,3 benzene
disulfonic acid (Tiron) for 24 h where indicated. Parental and
superoxide dismutase-expressing HeLa cells along with MCF-7 cells
expressing Bcl2 variants were also transfected as described above. The
coverslips were collected and fixed in 3.7% formaldehyde in 1×
phosphate-buffered saline (PBS). They were then washed twice for 5 min
with 500 µl in 1× PBS and 0.1% Nonidet P-40. In cells expressing
HA-tagged-MEKK1, rabbit polyclonal anti-MEKK1 (Santa Cruz) at a
dilution of 1:500 in 10% fetal bovine serum was incubated with the
coverslips for 1.5 h with gentle shaking. Secondary antibody
anti-rabbit fluorescein isothiocyanate (Chemicon) at a 1:5000 dilution
in 10% fetal bovine serum, 1× PBS, and 0.1% Nonidet P-40 was
incubated with the coverslip for 1.5 h with gentle shaking in the
dark. The exceptions were cells expressing GFP or GFP fused to MEKK1,
which were untreated. The coverslips were washed twice in 500 µl of
1× PBS and 0.1% Nonidet P-40 and incubated for 6 min in 1:2000
dilution of 20 mM Hoechst stain (Sigma) in 1× PBS and
0.1% Nonidet P-40 in the dark. Coverslips were mounted onto slides
with 4 µl of Fluoroguard antifade reagent (Bio-Rad). The condensed
DNA was determined by intense local staining of the DNA in nuclei by
Hoechst compared with the diffuse staining of the DNA in normal cells.
The percentage of apoptotic cells was determined from cells containing
normal DNA staining compared with cells with condensed DNA
fragmentation and morphological changes consistent with apoptotic
cells. No fewer than 200 cells were scored per sample. Fluorescence was visualized and captured using an Olympus fluorescent microscope equipped with a Spot camera.
Assessment of Cytochrome c Release--
HEK 293 cells were grown
on glass coverslips and transfected with GFP, MEKK1, truncated Bid
(tBid), and 91-kDa MEKK1 cDNA as previously described. The
coverslips were collected and fixed in 3.7% formaldehyde in 1× PBS.
They were then washed twice for 5 min with 500 µl in 1× PBS and
0.1% Nonidet P-40. Mouse anti-cytochrome c (Pharmingen) and
rabbit anti-MEKK1 or anti-Bid (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA) where indicated were diluted 1:500 in 10% fetal bovine
serum, 1× PBS, and 0.1% Nonidet P-40. The cells were then incubated
for 1.5 h with gentle shaking. The coverslips were washed twice in
500 µl of 1× PBS and 0.1% Nonidet P-40. Secondary antibody
anti-mouse cy3 or anti-rabbit fluorescein isothiocyanate (Chemicon) at
a 1:5000 dilution in 10% fetal bovine serum, 1× PBS, and 0.1%
Nonidet P-40 was incubated with the coverslip for 1.5 h with
gentle shaking in the dark. The secondary antibody was removed, and the
coverslips were incubated for 6 min in a 1:2000 dilution of 20 mM Hoechst stain (Sigma) in 1× PBS and 0.1% Nonidet P-40
in the dark. Coverslips were mounted onto slides with 4 µl of
Fluoroguard antifade reagent (Bio-Rad). No fewer than 200 cells were
scored per sample. Fluorescence was visualized and captured using a
Zeiss Axiphot microscope equipped with a cooled charged-coupled device
camera. For biochemical analysis of cytochrome c release,
transfected HEK 293 cells were resuspended in CFS buffer (10 mM Hepes, pH 7.4, 220 mM mannitol, 68 mM sucrose, 2 mM NaCl, 2.5 mM
KH2PO4, 0.5 mM EGTA, 2 mM MgCl2, 0.1 mM
phenylmethylsulfonyl fluoride, and 1 mM dithiothreitol) and
Dounce-homogenized (50 strokes). The cells were spun down at 3000 rpm
for 5 min at 4 °C. The supernatant was then centrifuged for 15 min
at 12,800 rpm at 4 °C. The pellet was resuspended in 30 µl of H
buffer (300 mM sucrose, 5 mM
2-{[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino}ethanesulfonic acid, and 200 µM EGTA) and represents the heavy membrane
fraction. The supernatant was spun down at 41,000 rpm for 1 h and
represents the cytosolic fraction. The fractions were loaded onto
SDS-polyacrylamide electrophoresis and Western blotted for cytochrome
c (anti-cytochrome c; Santa Cruz Biotechnology).
Immunoblots--
Cells were lysed in Nonidet P-40 lysis buffer
(50 mM HEPES, pH 7.25, 150 mM NaCl, 50 µM ZnCl2, 50 µM NaF, 2 mM EDTA, 1 mM sodium vanadate, 1.0% Nonidet
P-40, 2 mM phenylmethylsulfonyl fluoride). Cell debris was
removed by centrifugation at 8000 × g for 5 min, and
protein concentration was determined by a Bradford assay. 200-400 µg
of cell lysate protein was subject to SDS-polyacrylamide electrophoresis and transferred to nitrocellulose membranes. The membranes were blocked in Tris-buffered saline and 5% milk (w/v). Blots were incubated with the appropriate antibody concentration overnight (anti-MEKK1, anti-cytochrome c, and anti-HA were
purchased from Santa Cruz Biotechnology; anti-caspase 9 was purchased
from New England Biolabs), washed three times with 1× Tris-buffered saline, and incubated 1 h with the appropriate secondary antibody conjugated with alkaline phosphatase. Blots were visualized on x-ray
film with enhanced chemiluminescence reagents (PerkinElmer Life Sciences).
 |
RESULTS |
Overexpression of MEKK1 Suppresses 
m in the
Mitochondria--
HEK 293 cells were transiently transfected with GFP,
full-length MEKK1, and 91-kDa MEKK1. The cells were stained with the potentiometric dye TMRM, which detects 
m levels in
the mitochondria for 24 h as described under "Materials and
Methods," and then analyzed by flow cytometry. This showed that cells
expressing GFP have 20% 
m suppression (defined as
the reduction in mitochondrial membrane potential) while cells
expressing MEKK1 or 91-kDa MEKK1 have 40 and 49% 
m
suppression, respectively (Fig.
1A). Expression of the
kinase-inactive form of MEKK1 (MEKK1 KM) that prevents apoptosis failed
to suppress 
m (21%; Fig. 1A) as compared
with cells expressing only GFP. MEKK1 suppression of

m was further demonstrated by comparing GFP-positive
cells with TMRM-positive cells in a dot blot. In Fig. 1B,
there were 98 events for GFP-positive and TMRM-negative cells
(upper left quadrant), whereas 3535 events represented GFP- and TMRM-positive cells (upper
right quadrant) following analysis by flow
cytometry. In contrast, when GFP fused to MEKK1 was expressed, there
were 3216 events representing GFP-MEKK1 positive and TMRM-negative
cells (upper left quadrant), whereas 2738 events represented GFP-MEKK1- and TMRM-positive cells. In untransfected cells (lower quadrant of each dot
blot), there were 48 and 78 events (lower left
quadrant) for TMRM-negative cells, whereas 25,786 and 23,455 events (lower right quadrant) in
TMRM-positive cells were observed (Fig. 1B). This indicates
that expression of MEKK1 reduced the amount of TMRM-positive cells that
represents loss of 
m. Loss of 
m by
MEKK1 was further confirmed by immunohistochemical staining of HEK 293 cells with TMRM. Cells expressing only GFP showed mitochondrial
membrane potential as indicated by red fluorescence of TMRM staining,
whereas cells expressing GFP fused to full-length MEKK1 showed

m suppression as indicated by reduced TMRM staining (Fig. 1C). Some cells expressing the GFP-MEKK1 fusion
protein showed TMRM staining. This correlates to the ability to MEKK1 to suppress 
m in 40% of cells (Fig. 1A)
and induce apoptosis in 30% of cells after 24 h (data not shown).
Expression of kinase-inactive MEKK1 effectively blocked genotoxic agent
etoposide-induced apoptosis in HEK 293 cells (14). Treatment of HEK 293 cells expressing MEKK1 KM with etoposide also blocked

m suppression compared with vector alone cells over a
48-h time course (Fig. 1D).

View larger version (52K):
[in this window]
[in a new window]
|
Fig. 1.
MEKK1 suppresses
 m in HEK 293 cells.
A, HEK 293 cells were transfected with GFP alone or in
combination with MEKK1, 91-kDa MEKK1, or kinase-inactive MEKK1 (MEKK1
KM). After 24 h, the cells were then stained with 150 µM TMRM and analyzed on the flow cytometer. The cells
positive for green fluorescence were analyzed for the amount of TMRM
staining. The percentage of  m suppression was
calculated by the amount of reduction in TMRM staining. *,
statistically significant differences with p < 0.001. B, HEK 293 cells were transfected with GFP or GFP-MEKK1. The
cells were then analyzed on a flow cytometer. The amount of green
fluorescence-positive events was blotted compared with the number of
TMRM staining-positive events. The quadrants represent the
number of events positive for GFP, TMRM, or both. This is
representative of three separate experiments. C, HEK 293 cells were transiently transfected with GFP and GFP fused to
full-length MEKK1. The cells were stained with TMRM, and the amount of
staining was compared with expression of GFP or MEKK1. The cells were
analyzed on a confocal laser microscope as described under "Materials
and Methods." Cells were visualized using Nomarski. D,
vector alone- or MEKK1 KM-expressing HEK 293 cells were treated with
100 µM etoposide for a 48-h time course. At each time
interval, the cells were stained with TMRM and analyzed on a flow
cytometer. The percentage of  m suppression was
calculated as described above. S.D. values represent three independent
experiments.
|
|
Loss of 
m could be due to opening of the PT pore. To
confirm if MEKK1 is opening the PT pore to suppress

m, HEK 293 cells were stained with the mitochondrial
CalceinAM fluorescence dye. CalceinAM is freely permeable
across cellular membranes but becomes fluorescent (green) and
impermeable upon cleavage by intracellular esterases. This prevents its
exit from the mitochondria until the PT pore opens. Once the PT pore is
open, CalceinAM is released into the cytoplasm from the
mitochondria, where it is quenched by CoCl2 (added to the
cells along with CalceinAM). Using confocal laser
microscopy, HEK 293 cells expressing RFP alone or in combination with
MEKK1 or 91-kDa MEKK1 were analyzed for calcein fluorescence. In cells
expressing RFP alone, calcein fluorescence was punctate, indicating
that CalceinAM is localized in the mitochondria. However, in
cells expressing MEKK1 or 91-kDa MEKK1, calceinAM fluorescence was eliminated, indicating a release of calceinAM into the cytoplasm, where its fluorescence is quenched (Fig.
2A). Loss of

m could be due to membrane rupture or other open
channels in the mitochondria. To determine if MEKK1-mediated loss of

m was due to PT pore opening, the PT pore opening
inhibitor CsA was added to cells expressing MEKK1, and the amount of

m suppression was determined. GFP alone expression
failed to increase 
m suppression compared with cells
expressing GFP fused to MEKK1 (12% versus 45%; Fig. 2B). In the presence of CsA, the amount of

m suppression was reduced to 12% (Fig.
2B). CsA treatment failed to change the amount of

m suppression in cells expressing GFP alone (data not
shown). This indicates that the PT pore is open when MEKK1 is
expressed, causing loss of 
m.

View larger version (56K):
[in this window]
[in a new window]
|
Fig. 2.
MEKK1 expression and PT pore opening.
A, HEK 293 cells were transiently transfected with RFP alone
or in combination with MEKK1 or 91-kDa MEKK1. The cells were then
stained with 5 mM CalceinAM and treated with 5 mM CoCl2 and analyzed on a confocal laser
microscope. The arrows indicate cells expressing RFP alone,
MEKK1, or 91-kDa MEKK1 in each panel. Cells were visualized
using Nomarski. B, HEK 293 cells were transiently
transfected with GFP and GFP fused to MEKK1. In cells expressing MEKK1,
the cells were exposed to 20 µM CsA or untreated as
indicated. The cells were incubated for 24 h and then stained with
150 µM TMRM. The cells were analyzed on a flow cytometer.
S.D. values were calculated from three independent experiments.
|
|
MEKK1 Fails to Release Cytochrome c from the
Mitochondria--
In addition to changes in membrane potential,
mitochondrial cytochrome c release occurs during apoptosis,
leading to caspase activation (1). We investigated the ability of MEKK1
to release cytochrome c from the mitochondria. HEK 293 cells
were transfected with vector alone, MEKK1, or 91-kDa MEKK1. The cells
were then immunohistochemically stained for cytochrome c and
MEKK1. In vector alone, cytochrome c staining was punctate,
indicating that it is localized in the mitochondria. Using a
mitochondria-specific stain (Mitotracker), a similar staining
pattern was observed (data not shown). In cells expressing MEKK1 and
91-kDa MEKK1, the same punctate staining was present as in vector alone
cells (Fig. 3A). As a positive
control, truncated Bcl2 family member BID (tBid), which has previously
been shown to release cytochrome c from the mitochondria,
was expressed in HEK 293 cells (Fig. 3A). Upon expression, there was reduced staining for cytochrome c in cells,
indicating release of cytochrome c into the cytosol. To
further confirm these results, membrane and cytosolic fractions were
isolated from these cells and Western blotted for the presence of
cytochrome c. In cells expressing MEKK1, cytochrome
c failed to be detected in the cytosolic fraction but was
present in the membrane-bound fraction (Fig. 3B). Cytochrome
c was, however, found in the cytosolic fraction following
tBid expression (Fig. 3B). These same results were also observed over a 72-h time course, where the cells expressing MEKK1 were
also observed undergoing apoptosis as determined by DNA condensation (data not shown). In addition, caspase 9 activation was determined by
Western blotting for the inactive procaspase form of caspase 9. When
vector alone or MEKK1 was transfected into HEK 293 cells, the level of
caspase 9 remained unchanged, but when tBid was overexpressed, caspase
9 was cleaved into its active form (Fig. 3C). This indicates that MEKK1 fails to activate caspase 9.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 3.
MEKK1 expression fails to release cytochrome
c from the mitochondria. A, HEK 293 cells were transiently transfected by vector alone, MEKK1, 91-kDa
MEKK1, or tBid for 24 h. The cells were fixed and stained for
cytochrome c with a mouse monoclonal antibody against
cytochrome c and stained for MEKK1 with a rabbit polyclonal
antibody against HA tag fused to MEKK1. For cells expressing tBid, tBid
was stained with rabbit polyclonal antibodies against Bid. The proteins
were detected by anti-mouse antibodies conjugated to Cy3
(red) for cytochrome c and by anti-rabbit
antibodies conjugated to fluorescein isothiocyanate (green)
for MEKK1 or tBid as indicated. The nucleus was stained with Hoechst.
The arrows indicate an individual cell stained in each of
the four panels. All experiments were repeated three
independent times. B, HEK 293 cells were transiently
transfected with vector alone, MEKK1, or tBid for 24 h. The cells
were then lysed, and membrane and cytosolic fractions were isolated as
described under "Materials and Methods." The lysate was Western
blotted with antibodies against cytochrome c. The membrane
fraction (lanes M) and cytosolic
(lanes C) fractions were isolated under
each condition indicated. This experiment was repeated three
independent times. C, HEK 293 cells were transfected with
vector alone (lane 1), MEKK1 (lane
2), or tBid (lane 3) for 24 h.
The cells were lysed and Western blotted with antibodies recognizing
the inactive form of caspase 9. -Actin expression was also Western
blotted for equal loading.
|
|
Blockage of PT Pore Opening and of Reactive Oxygen Species
Production Effectively Inhibits MEKK1-induced Apoptosis--
Our data
indicate that the overexpression of MEKK1 leads to 
m
suppression in the mitochondria mediated by PT pore opening. We further
investigated if blockage of PT pore opening by treatment with CsA or
blockage of reactive oxygen species production inhibits MEKK1-induced
apoptosis. HEK 293 cells were transiently transfected with MEKK1 in the
absence or presence of CsA. CsA effectively inhibited MEKK1-induced
apoptosis (Fig. 4A).

m suppression also associated with increased
production of ROS. Using a free radical scavenger agent, Tiron, HEK 293 cells were transiently transfected with MEKK1 in the presence and
absence of Tiron. In the presence of Tiron, MEKK1-induced apoptosis was
blocked (Fig. 4B). To further confirm the involvement of ROS
in MEKK1 induction of apoptosis, HeLa cells overexpressing superoxide
dismutase, which eliminates accumulation of ROS, were transiently
transfected with MEKK1. As a control, parental HeLa cells were also
transiently transfected with MEKK1. The cells were then stained for DNA
and MEKK1, and the amount of apoptosis in MEKK1-expressing cells was
determined by DNA condensation. When superoxide dismutase was
overexpressed, MEKK1-induced apoptosis was also blocked as compared
with parental cells (Fig. 4C). These results indicate that
PT pore opening and production of ROS is involved in MEKK1-induced
apoptosis.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 4.
Blockage of PT pore opening and reactive
oxygen species protection and MEKK1-induced
apoptosis. A, HEK 293 cells were transiently
transfected with GFP or MEKK1 fused with GFP. The cells were then
treated with the PT pore inhibitor CsA (20 µM) for
24 h. The cells were then fixed and stained with Hoechst. The
amount of apoptosis was determined by DNA condensation on an Olympus
fluorescent microscope. B, HEK 293 cells were also
transiently transfected with GFP or MEKK1 fused with GFP and at the
same time treated with the free radical scavenger Tiron (5 mM) for 24 h. After 24-h incubation, the cells were
fixed and stained with Hoechst. The amount of apoptosis was determined
as in A. C, HeLa cells parental or expressing
superoxide dismutase (SOD) were transiently transfected with
GFP or MEKK1 fused to GFP. The cells were incubated for 24 h. The
cells were then fixed and stained with Hoechst. The amount of apoptosis
was determined as described above. S.D. values were determined by three
independent experiments.
|
|
Bcl2 Targeted to the Mitochondria Prevents MEKK1-induced Apoptosis
but Fails to Prevent Cleavage of MEKK1--
We have previously shown
that Bcl2 prevents MEKK1-induced apoptosis. Bcl2 has also been
shown to block permeability transition in the mitochondria. Using the
breast cancer cell line MCF7 expressing vector alone, Bcl2 wild type
(Bcl2-wt), and Bcl2 targeted to the mitochondria (Bcl2-mito) (17, 19,
20), the ability of GFP, MEKK1, or 91-kDa MEKK1 to induce apoptosis was
determined. These cells were transiently transfected with GFP, MEKK1,
or 91-kDa MEKK1, and the amount of apoptosis was determined by DNA
condensation. Both MEKK1 and 91-kDa MEKK1 were able to induce apoptosis
in MCF7 cells expressing vector alone (39 and 44%, respectively),
whereas GFP failed to induce apoptosis (14%; Fig.
5A). MEKK1 and 91-kDa MEKK1
induction of apoptosis was inhibited in MCF7 cells expressing Bcl2-wt
(21 and 25%, respectively) and Bcl2-mito (19 and 28%) (Fig.
5A). MEKK1-induced 
m suppression was also
blocked in HEK 293 cells expressing Bcl2 (data not shown). This
indicates that Bcl2 blocks MEKK1-induced apoptosis at the
mitochondria.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 5.
Bcl2 blocks MEKK1-induced apoptosis at the
mitochondria. The breast cancer cell line MCF-7 expressing vector
alone, Bcl2 wild type (Bcl2-wt), and Bcl2 targeted to the
mitochondria (Bcl2-mito) were transiently transfected with
GFP, MEKK1, or 91-kDa MEKK1. The cells were then fixed and stained for
MEKK1 and DNA. The amount of apoptosis was determined by DNA
condensation. S.D. values represent three independent experiments.
B, HEK 293 cells expressing vector alone or Bcl2 were
untreated or treated with 100 µM etoposide for 24 h.
The cells were lysed and Western blocked for MEKK1. C, HEK
293 cells were also transiently transfected with HA-tagged MEKK1 and
lysed after 24 h of incubation. The lysate was Western blotted
with antibodies against HA. The arrows represent the cleaved
fragments of MEKK1.
|
|
MEKK1 is cleaved following treatment with genotoxins such as etoposide
and following overexpression in HEK 293 cells (12-14). Etoposide
treatment of HEK 293 cells expressing Bcl2 leads to the cleavage of
MEKK1 similar to HEK 293 cells expressing vector alone (Fig.
5B). Increased Bcl2 expression, however, was effective at
inhibiting etoposide-induced apoptosis (data not shown).
Overexpression of MEKK1 in HEK 293 cells expressing Bcl2 also failed to
block MEKK1 cleavage (Fig. 5C). This suggests that Bcl2
blocks MEKK1-induced apoptosis downstream of MEKK1 cleavage.
Cleavage of MEKK1 by Caspase 3 Is Required for 
m
Suppression--
MEKK1 is cleaved during apoptosis mediated by caspase
3-like molecules (12-14). To determine whether caspase 3 plays a role in MEKK1-induced apoptosis and 
m suppression, we
investigated primary MEFs lacking caspase 3 expression. MEF cells
lacking caspase 3 were transiently transfected with GFP, MEKK1, or
91-kDa MEKK1. The cells were stained for DNA and MEKK1 expression, and
the amount of apoptotic cells was determined by DNA condensation.
Expression of MEKK1 caused apoptosis in wild type MEF cells
(33%) but was significantly reduced in MEF cells lacking caspase 3 (20%) as compared with GFP expression (9.5 and 15%, respectively;
Fig. 6A). In contrast, 91-kDa
MEKK1 expression was found to induce apoptosis in both wild type and
caspase 3-lacking cells (49 and 43%, respectively; Fig.
6A). MEKK1 and 91-kDa MEKK1 induced 
m suppression in wild type cells, but only 91-kDa MEKK1 induced 
m suppression in MEF cells lacking caspase 3 (Fig.
6B). This correlates with the ability of 91-kDa MEKK1 to
induce apoptosis in wild type and caspase 3-lacking MEF cells, whereas
full-length MEKK1 only induces apoptosis in wild type MEF cells.
Treatment of MEF cells lacking caspase 3 with etoposide revealed that
MEKK1 failed to be cleaved, whereas MEF wild type cells treated with etoposide caused cleavage of MEKK1 (data not shown). This indicates that 
m suppression in the mitochondria occurs
downstream of MEKK1 cleavage.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 6.
Mouse embryonic fibroblast cells lacking
caspase 3 expression are resistant to full-length MEKK1-induced
apoptosis and loss of
 m. MEFs, wild type
and lacking expression of caspase 3 (caspase 3 / ), were transiently transfected with GFP alone or in combination
with MEKK1 or 91-kDa MEKK1 for 24 h. A, the cells
were then fixed and stained for MEKK1 and DNA as described in
the legend to Fig. 4. The amount of apoptosis was determined. S.D.
values represent three independent experiments. B, the
transfected cells described above were stained with 150 µM TMRM and analyzed on a confocal laser microscope for
loss of  m and MEKK1 full-length and 91-kDa expression
as indicated. For MEKK1 (full-length) expression in MEF wild type
cells, magnification was increased for better resolution compared with
the other panels. These results are representative of three
independent experiments. The arrows represent cells
expressing GFP, MEKK1, or 91-kDa MEKK1 in each of the
panels.
|
|
 |
DISCUSSION |
Full-length MEKK1 is activated during apoptosis and has been
implicated in the induction of apoptosis (13, 16, 21, 22). This is
partially mediated by MEKK1 up-regulating proapoptotic genes such
as death receptors (15, 21, 23). This up-regulation contributes to
genotoxin-induced apoptosis. In contrast, activation of MEKK1 also
occurs following treatment with nonapoptotic stimuli such as growth
factors (24, 25). Furthermore, MEKK1 is activated by and might protect
cells from microtubule toxin-induced apoptosis (14, 26). MEKK1,
however, fails to be cleaved following treatment with growth factors or
microtubule toxins. Thus, activation of full-length MEKK1 is not
sufficient to induce an apoptotic response, suggesting that cleavage of
MEKK1 is required for its pro-apoptotic function.
Regulation of MEKK1 induction of apoptosis involves the
cleavage of MEKK1 into a 91-kDa kinase fragment (13). This fragment is
a potent inducer of apoptosis, and blockage of the cleavage site in
MEKK1 that produces the 91-kDa fragment fails to induce apoptosis (13).
The mechanism of 91-kDa MEKK1 induction of apoptosis was, however,
unknown. We have demonstrated that cleaved MEKK1 leads to permeability
transition in the mitochondria. Blockage of PT pore opening inhibits
MEKK1-induced apoptosis. The importance of cleavage of MEKK1 was
demonstrated in MEF cells lacking caspase 3. This showed that only
91-kDa MEKK1 induces apoptosis and permeability transition in these
cells. In contrast, MCF-7 cells that lack caspase 3 expression undergo
apoptosis following overexpression of MEKK1. MEKK1 is also cleaved
following etoposide treatment in MCF-7
cells.2 In addition,
treatment of these cells with doxorubicin induces apoptosis where
doxorubicin fails to induce apoptosis in MEF cells lacking caspase
3 (27, 28). This suggests that MCF-7 cells have bypassed the
requirement of caspase 3 to induce apoptosis and illustrates potential
differences between primary cells (MEF cells) and transformed cell
lines (MCF-7 cells) in inducing apoptosis. Overall, we have
demonstrated that MEKK1 induction of apoptosis involves cleavage
into its 91-kDa form that leads to 
m suppression in
the mitochondria.
MEKK1, unlike other proapoptotic proteins, fails to release cytochrome
c from the mitochondria. This suggests that MEKK1-mediated caspase activation is independent of mitochondrial cytochrome c release, and loss of 
m is not sufficient
to release cytochrome c. Full-length MEKK1 up-regulates
death receptors that could activate caspases independent of the
mitochondria (15, 29). In addition, caspase 3 activation is required
for full-length MEKK1-induced loss of 
m and
apoptosis, suggesting that caspase activation occurs prior to
MEKK1-induced mitochondria permeability transition. Alternatively,
cleavage of MEKK1 could also lead to the activation of signaling
pathways that further activate caspases independent of mitochrondrial
cytochrome c release. Nevertheless, MEKK1 induces 
m suppression independent of cytochrome c
release, indicating that cytochrome c release is not
involved in MEKK1-mediated caspase activation.
Bcl2 family members regulate mitochondrial permeability
transition (11). We have demonstrated that Bcl2 negatively regulates MEKK1-induced apoptosis, and this is downstream of MEKK1 cleavage and
occurs at the mitochondria. This suggests that pro-apoptotic Bcl2
family members are involved in MEKK1-induced apoptosis. Indeed, these
proteins are translocated from the cytoplasm to the mitochondria during
the induction of apoptosis (11). It has been reported that
expression of the kinase domain MEKK1 translocates pro-apoptotic Bcl2
family member Bak to the mitochondria. The kinase-inactive form of
MEKK1 kinase domain blocks this translocation and prevents cisplatin-induced apoptosis (30). Most of these pro-apoptotic proteins
including Bak cause release of cytochrome c from the mitochondria (11), but MEKK1 overexpression fails to release cytochrome
c, and the significance of pro-apoptotic Bcl2 family members such as Bak in regulating MEKK1-induced apoptosis is unclear. A
new Bcl2 family member BNIP3 has been shown to localize to the mitochondria and induces permeability transition without the subsequent release of cytochrome c (31, 32). BNIP3, however, fails to induce apoptosis but instead induces a necrotic-like cell death. Whatever the pro-apoptotic Bcl2 family member responsible for MEKK1-induced loss of 
m and apoptosis, Bcl2
negatively regulates MEKK1-induced apoptosis at the mitochondria
downstream of MEKK1 cleavage. The proapoptotic Bcl2 family member
responsible for MEKK1-induced mitochondrial permeability transition
will be further investigated.
The apoptotic signaling pathways leading to mitochondrial
permeability transition are not well defined. MEKK1 is a serine threonine kinase that when cleaved following apoptotic stimulus leads
to permeability transition, further committing cells to undergo
apoptosis. We have demonstrated that kinase activity and cleavage of
MEKK1 are required for mitochondrial permeability transition. MEKK1
activates many signaling pathways. In particular, Jun N-terminal kinase
activation is regulated by MEKK1 (26, 33). Jun N-terminal kinase has
been shown to phosphorylate Bcl2 family members, inhibiting their
anti-apoptotic functions (34, 35). This could explain the changes in
mitochondrial permeability transition. Overexpression of MEKK1,
however, does not lead to the phosphorylation of Bcl2 or
BclxL proteins as determined by changes in gel mobility of
these proteins.3 Furthermore,
this phosphorylation has also been demonstrated to induce the release
of cytochrome c from the mitochondria but not

m suppression. Finally, expression of kinase inactive
MEKK1 prevents genotoxin-induced apoptosis but fails to block Jun
N-terminal kinase activation in various cell types (14, 30). MEKK1 also activates other pathways leading to activation transcription factors such as NF-
B (22, 36). This could induce gene expression of a
molecule that opens the PT pore such as pro-apoptotic Bcl2 family
members without cytochrome c release. Alternatively, MEKK1 could directly phosphorylate proteins that control PT pore opening. The
exact substrate(s) for MEKK1 activation specifically leading to changes
in mitochondrial permeability transition remains unknown and will be
the focus of further investigation.
Overall, these results indicate that MEKK1 apoptosis signaling involves
mitochondrial permeability transition but is independent of cytochrome
c release. This occurs downstream of MEKK1 cleavage, committing cells to undergo apoptosis. By pharmaceutically targeting the cleavage of MEKK1, MEKK1-induced apoptosis could be effectively regulated without affecting the other functions of full-length MEKK1.
This could be used in the treatment of various diseases such as cancer.
 |
FOOTNOTES |
*
This work was supported by grants from the Canadian
Institutes of Health Research and Cancer Care Manitoba Foundation.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: Manitoba Institute of
Cell Biology, 675 McDermot Ave., Winnipeg, Manitoba R3E 0V9, Canada.
Tel.: 204-787-2051; Fax: 204-787-2190; E-mail:
gibsonsb@cc.umanitoba.ca.
Published, JBC Papers in Press, December 26, 2001, DOI 10.1074/jbc.M108366200
2
E. M. Gibson, E. S. Henson, J. Onio,
and S. B. Gibson, unpublished data.
3
G. L. Johnson, personal communication.
 |
ABBREVIATIONS |
The abbreviations used are:
ROS, reactive oxygen
species;
PT, permeability transition;
MEKK1, MEK kinase 1;
MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase
kinase;
MEF, mouse embryonic fibroblasts;
HEK, human embryonic kidney;
GFP, green fluorescent protein;
HBSS, Hepes-buffered saline solution;
TMRM, tetramethylrhodamine;
RFP, red fluorescent protein;
CsA, cyclosporin A;
PBS, phosphate-buffered saline;
HA, hemagglutinin;
tBid, truncated Bid.
 |
REFERENCES |
| 1.
|
Lee, H.,
and Wei, Y.
(2000)
J. Biomed. Sci.
7,
2-15[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Adler, V.,
Yin, Z.,
Tew, K. D.,
and Ronai, Z.
(1999)
Oncogene
18,
6104-6111[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Budihardjo, I.,
Oliver, H.,
Lutter, M.,
Luo, X.,
and Wang, X.
(1999)
Annu. Rev. Cell Dev. Biol.
15,
269-290[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Morin, D.,
Hauet, T.,
Spedding, M.,
and Tillement, J.
(2001)
Adv. Drug Deliv. Rev.
49,
151-174[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Green, D. R.,
and Reed, J. C.
(1998)
Science
281,
1309-1312[Abstract/Free Full Text]
|
| 6.
|
Loeffler, M.,
and Kroemer, G.
(2000)
Exp. Cell Res.
256,
19-26[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Halestrap, A. P.,
Doran, E.,
Gillespie, J. P.,
and O'Toole, A.
(2000)
Biochem. Soc. Trans.
28,
170-177[Medline]
[Order article via Infotrieve]
|
| 8.
|
Kumar, S.
(1999)
Cell Death Differ.
6,
1060-1066[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Adams, J. M.,
and Cory, S.
(1998)
Science
281,
1322-1326[Abstract/Free Full Text]
|
| 10.
|
Antonsson, B.,
and Martinou, J. C.
(2000)
Exp. Cell Res.
256,
50-57[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Gross, A.,
McDonnell, J. M.,
and Korsmeyer, S. J.
(1999)
Genes Dev.
13,
1899-1911[Free Full Text]
|
| 12.
|
Widmann, C.,
Gibson, S.,
and Johnson, G. L.
(1998)
J. Biol. Chem.
273,
7141-7147[Abstract/Free Full Text]
|
| 13.
|
Widmann, C.,
Gerwins, P.,
Johnson, N. L.,
Jarpe, M. B.,
and Johnson, G. L.
(1998)
Mol. Cell. Biol.
18,
2416-2429[Abstract/Free Full Text]
|
| 14.
|
Gibson, S.,
Widmann, C.,
and Johnson, G. L.
(1999)
J. Biol. Chem.
274,
10916-10922[Abstract/Free Full Text]
|
| 15.
|
Gibson, S. B.,
Oyer, R.,
Spalding, A. C.,
Anderson, S. M.,
and Johnson, G. L.
(2000)
Mol. Cell. Biol.
20,
205-212[Abstract/Free Full Text]
|
| 16.
|
Widmann, C.,
Johnson, N. L.,
Gardner, A. M.,
Smith, R. J.,
and Johnson, G. L.
(1997)
Oncogene
15,
2439-2447[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Annis, M. G.,
Zamzami, N.,
Zhu, W.,
Penn, L. Z.,
Kroemer, G.,
Leber, B.,
and Andrews, D. W.
(2001)
Oncogene
20,
1939-1952[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Petronilli, V.,
Penzo, D.,
Scorrano, L.,
Bernardi, P.,
and Di Lisa, F.
(2001)
J. Biol. Chem.
276,
12030-12034[Abstract/Free Full Text]
|
| 19.
|
Brenner, C.,
Cadiou, H.,
Vieira, H. L.,
Zamzami, N.,
Marzo, I.,
Xie, Z.,
Leber, B.,
Andrews, D.,
Duclohier, H.,
Reed, J. C.,
and Kroemer, G.
(2000)
Oncogene
19,
329-336[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Lee, S. T.,
Hoeflich, K. P.,
Wasfy, G. W.,
Woodgett, J. R.,
Leber, B.,
Andrews, D. W.,
Hedley, D. W.,
and Penn, L. Z.
(1999)
Oncogene
18,
3520-3528[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Faris, M.,
Latinis, K. M.,
Kempiak, S. J.,
Koretzky, G. A.,
and Nel, A.
(1998)
Mol. Cell. Biol.
18,
5414-5424[Abstract/Free Full Text]
|
| 22.
|
Yin, M. J.,
Christerson, L. B.,
Yamamoto, Y.,
Kwak, Y. T., Xu, S.,
Mercurio, F.,
Barbosa, M.,
Cobb, M. H.,
and Gaynor, R. B.
(1998)
Cell
93,
875-884[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Deak, J. C.,
Cross, J. V.,
Lewis, M.,
Qian, Y.,
Parrott, L. A.,
Distelhorst, C. W.,
and Templeton, D. J.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
5595-5600[Abstract/Free Full Text]
|
| 24.
|
Fanger, G. R.,
Gerwins, P.,
Widmann, C.,
Jarpe, M. B.,
and Johnson, G. L.
(1997)
Curr. Opin. Genet. Dev.
7,
67-74[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Jarpe, M. B.,
Widmann, C.,
Knall, C.,
Schlesinger, T. K.,
Gibson, S.,
Yujiri, T.,
Fanger, G. R.,
Gelfand, E. W.,
and Johnson, G. L.
(1998)
Oncogene
17,
1475-1482[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Yujiri, T.,
Fanger, G. R.,
Garrington, T. P.,
Schlesinger, T. K.,
Gibson, S.,
and Johnson, G. L.
(1999)
J. Biol. Chem.
274,
12605-12610[Abstract/Free Full Text]
|
| 27.
|
Weldon, C. B.,
Burow, M. E.,
Rolfe, K. W.,
Clayton, J. L.,
Jaffe, B. M.,
and Beckman, B. S.
(2001)
Surgery
130,
143-150[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Woo, M.,
Hakem, R.,
Soengas, M. S.,
Duncan, G. S.,
Shahinian, A.,
Kagi, D.,
Hakem, A.,
McCurrach, M.,
Khoo, W.,
Kaufman, S. A.,
Senaldi, G.,
Howard, T.,
Lowe, S. W.,
and Mak, T. W.
(1998)
Genes Dev.
12,
806-819[Abstract/Free Full Text]
|
| 29.
|
Ashkenazi, A.,
and Dixit, V. M.
(1998)
Science
281,
1305-1308[Abstract/Free Full Text]
|
| 30.
|
Mandic, A.,
Viktorsson, K.,
Molin, M.,
Akusjarvi, G.,
Eguchi, H.,
Hayashi, S. I.,
Toi, M.,
Hansson, J.,
Linder, S.,
and Shoshan, M. C.
(2001)
Mol. Cell. Biol.
21,
3684-3691[Abstract/Free Full Text]
|
| 31.
|
Cizeau, J.,
Ray, R.,
Chen, G.,
Gietz, R. D.,
and Greenberg, A. H.
(2000)
Oncogene
19,
5453-5463[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Vande Velde, C.,
Cizeau, J.,
Dubik, D.,
Alimonti, J.,
Brown, T.,
Israels, S.,
Hakem, R.,
and Greenberg, A. H.
(2000)
Mol. Cell. Biol.
20,
5454-5468[Abstract/Free Full Text]
|
| 33.
|
Yujiri, T.,
Sather, S.,
Fanger, G. R.,
and Johnson, G. L.
(1998)
Science
282,
1911-1914[Abstract/Free Full Text]
|
| 34.
|
Deng, X.,
Xiao, L.,
Lang, W.,
Gao, F.,
Ruvolo, P.,
and May, W. S., Jr.
(2001)
J. Biol. Chem.
276,
23681-23688[Abstract/Free Full Text]
|
| 35.
|
Yamamoto, K.,
Ichijo, H.,
and Korsmeyer, S. J.
(1999)
Mol. Cell. Biol.
19,
8469-8478[Abstract/Free Full Text]
|
| 36.
|
Nemoto, S.,
DiDonato, J. A.,
and Lin, A.
(1998)
Mol. Cell. Biol.
18,
7336-7343[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
B. McElhinney, M. E. Poynter, P. Shrivastava, S. L. Hazen, and Y. M. W. Janssen-Heininger
Eosinophil peroxidase catalyzes JNK-mediated membrane blebbing in a Rho kinase-dependent manner
J. Leukoc. Biol.,
November 1, 2003;
74(5):
897 - 907.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. H. Dho and K.-S. Kwon
The Ret Finger Protein Induces Apoptosis via Its RING Finger-B Box-Coiled-coil Motif
J. Biol. Chem.,
August 22, 2003;
278(34):
31902 - 31908.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Chauhan, G. Li, T. Hideshima, K. Podar, C. Mitsiades, N. Mitsiades, N. Munshi, S. Kharbanda, and K. C. Anderson
JNK-dependent Release of Mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) Cells
J. Biol. Chem.,
May 9, 2003;
278(20):
17593 - 17596.
[Abstract]
[Full Text]
[PDF]
|
 |
|